董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Herriot Tabuteau | 男 | Chief Executive Officer, President, and Chairman of the Board | 48 | 1028.35万美元 | 935.77 | 2017-04-21 |
| Mark Coleman | 男 | Director | 49 | 51.47万美元 | 64.15 | 2017-04-21 |
| Mark Saad | 男 | Director | 47 | 48.81万美元 | 21.74 | 2017-04-21 |
| Roger Jeffs | 男 | Director | 55 | 48.24万美元 | 21.03 | 2017-04-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Herriot Tabuteau | 男 | Chief Executive Officer, President, and Chairman of the Board | 48 | 1028.35万美元 | 935.77 | 2017-04-21 |
| Constance Ames | 女 | Vice President, Finance and Treasurer | 30 | 40.98万美元 | 未持股 | 2017-04-21 |
董事简历
中英对照 | 中文 | 英文- Herriot Tabuteau
-
Herriot Tabuteau，本公司的创始人，自2012年1月本公司成立之时起，担任首席执行官、董事长。他还是Antecip Capital LLC（原Versant Capital Management LLC）的创始人，这是本公司的大股东之一；2003年起，担任其管理合伙人。他还是Antecip Bioventures II LLC的管理合伙人。创办本公司之前，他是 Healthco/S.A.C. Capital （现HealthCor） 的高级分析师、合伙人，负责生物技术、基因组、仪表行业投资组合。此前，他是Kingdon Capital的医疗保健行业分析师。职业生涯之初，他是Goldman Sachs的投资银行分析师，后来成为Banc of America Securities的高级研究分析师，负责医院供应品行业。他在Yale University School of Medicine获得医学博士学位，在Wesleyan University获得分子生物与生物化学学士学位。
Herriot Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. He is also the founder of Antecip Capital LLC formerly Versant Capital Management LLC, one of our principal stockholders, for which Dr. Tabuteau has been the managing member since 2003. Dr. Tabuteau is also the managing member of Antecip Bioventures II LLC. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University. - Herriot Tabuteau，本公司的创始人，自2012年1月本公司成立之时起，担任首席执行官、董事长。他还是Antecip Capital LLC（原Versant Capital Management LLC）的创始人，这是本公司的大股东之一；2003年起，担任其管理合伙人。他还是Antecip Bioventures II LLC的管理合伙人。创办本公司之前，他是 Healthco/S.A.C. Capital （现HealthCor） 的高级分析师、合伙人，负责生物技术、基因组、仪表行业投资组合。此前，他是Kingdon Capital的医疗保健行业分析师。职业生涯之初，他是Goldman Sachs的投资银行分析师，后来成为Banc of America Securities的高级研究分析师，负责医院供应品行业。他在Yale University School of Medicine获得医学博士学位，在Wesleyan University获得分子生物与生物化学学士学位。
- Herriot Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. He is also the founder of Antecip Capital LLC formerly Versant Capital Management LLC, one of our principal stockholders, for which Dr. Tabuteau has been the managing member since 2003. Dr. Tabuteau is also the managing member of Antecip Bioventures II LLC. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.
- Mark Coleman
-
Mark Coleman，2014年12月以来，一直担任本公司董事。另外，2012-2014，他是本公司的顾问。他从2005年起，担任National Spine and Pain Centers（NSPC）巴尔的摩分支的医学总监，这是全国最大的介入性疼痛管理集团；2009-2011，担任NSPC的新型疗法总监。NSPC定期通过临床试验评估新兴的疼痛疗法。他是the American Board of Anesthesiology醉和疼痛管理方面的外交官。他在Johns Hopkins University School of Medicine获得医学博士学位，在Wesleyan University获得本科学位。
Mark Coleman has been a member of board of directors since December 2014. In addition, from 2012 to 2014 Dr. Coleman served as a consultant to us. Since 2005 Dr. Coleman has served as the Medical Director of the Baltimore branch of National Spine and Pain Centers, or NSPC, the nation's largest interventional pain management group. Dr. Coleman served as Director of Novel Therapies at NSPC from 2009 to 2011. NSPC routinely evaluates emerging treatments for pain through the conduct of clinical trials. Dr. Coleman is a Diplomat of the American Board of Anesthesiology in Anesthesiology and Pain Management. Dr. Coleman holds an M.D. from Johns Hopkins University School of Medicine and received his undergraduate degree from Wesleyan University. - Mark Coleman，2014年12月以来，一直担任本公司董事。另外，2012-2014，他是本公司的顾问。他从2005年起，担任National Spine and Pain Centers（NSPC）巴尔的摩分支的医学总监，这是全国最大的介入性疼痛管理集团；2009-2011，担任NSPC的新型疗法总监。NSPC定期通过临床试验评估新兴的疼痛疗法。他是the American Board of Anesthesiology醉和疼痛管理方面的外交官。他在Johns Hopkins University School of Medicine获得医学博士学位，在Wesleyan University获得本科学位。
- Mark Coleman has been a member of board of directors since December 2014. In addition, from 2012 to 2014 Dr. Coleman served as a consultant to us. Since 2005 Dr. Coleman has served as the Medical Director of the Baltimore branch of National Spine and Pain Centers, or NSPC, the nation's largest interventional pain management group. Dr. Coleman served as Director of Novel Therapies at NSPC from 2009 to 2011. NSPC routinely evaluates emerging treatments for pain through the conduct of clinical trials. Dr. Coleman is a Diplomat of the American Board of Anesthesiology in Anesthesiology and Pain Management. Dr. Coleman holds an M.D. from Johns Hopkins University School of Medicine and received his undergraduate degree from Wesleyan University.
- Mark Saad
-
Mark Saad，2014年12月以来，一直担任本公司董事。从2014年8月起，他担任RuiYi, Inc.的首席财务官，这是全球性的治疗创新者，目前正推进以第一类单克隆抗体一个管道成为经验证的G蛋白偶联受体的GPCR。此前，2004-2014，他担任Cytori Therapeutics的首席财务官，负责财务与会计、业务开发、及其它运营职责。加入Cytori之前，他是UBS Investment Bank的执行总监，曾担任的全球医疗保健部的首席运营官。加入UBS之前，他任职于Salomon Smith Barney的健康护理投资银行部。他在Villanova University获得学士学位。
Mark Saad has been a member of board of directors since December 2014. Mr. Saad is currently a Partner and Chief Operating Officer of Alethea Capital Management, LLC, an asset management firm based in San Diego. Between August 2014 and February 2017 he served as the Chief Financial Officer of Bird Rock Bio, Inc., a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Previously, he served as Chief Financial Officer of Cytori Therapeutics from 2004 to 2014 where he was responsible for finance and accounting, business development, and other operating functions. Prior to Cytori, he served as Executive Director of UBS Investment Bank, where he was the Chief Operating Officer of the Global Healthcare Group. Prior to UBS, Mr. Saad was part of the Health Care Investment Banking Group at Salomon Smith Barney. Mr. Saad holds a Bachelor of Arts from Villanova University. - Mark Saad，2014年12月以来，一直担任本公司董事。从2014年8月起，他担任RuiYi, Inc.的首席财务官，这是全球性的治疗创新者，目前正推进以第一类单克隆抗体一个管道成为经验证的G蛋白偶联受体的GPCR。此前，2004-2014，他担任Cytori Therapeutics的首席财务官，负责财务与会计、业务开发、及其它运营职责。加入Cytori之前，他是UBS Investment Bank的执行总监，曾担任的全球医疗保健部的首席运营官。加入UBS之前，他任职于Salomon Smith Barney的健康护理投资银行部。他在Villanova University获得学士学位。
- Mark Saad has been a member of board of directors since December 2014. Mr. Saad is currently a Partner and Chief Operating Officer of Alethea Capital Management, LLC, an asset management firm based in San Diego. Between August 2014 and February 2017 he served as the Chief Financial Officer of Bird Rock Bio, Inc., a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Previously, he served as Chief Financial Officer of Cytori Therapeutics from 2004 to 2014 where he was responsible for finance and accounting, business development, and other operating functions. Prior to Cytori, he served as Executive Director of UBS Investment Bank, where he was the Chief Operating Officer of the Global Healthcare Group. Prior to UBS, Mr. Saad was part of the Health Care Investment Banking Group at Salomon Smith Barney. Mr. Saad holds a Bachelor of Arts from Villanova University.
- Roger Jeffs
-
Roger Jeffs，他获得杜克大学（Duke University）的化学学士学位，并获得the University of North Carolina的药理学博士学位。他于1998年加入United Therapeutics公司，并担任研究、开发和医疗董事。他于2000年被任命为研究、开发和医疗的副总裁，并于2001年担任现任职务，即总裁兼首席营运官。从1993年到1995年，他曾任职Burroughs Wellcome & Company，在那里他曾担任Flolan（美国fda批准的首个治疗肺动脉高血压患者药物）的临床研究小组的一员。从1995年到1998年，他曾任职Amgen公司，在那里他曾担任全球临床传染病项目的领导人。他目前领导我们的全球临床、商业、制造业、监管、药物警戒和业务开发工作。自2002年以来，他担任United Therapeutics公司的董事。
Roger Jeffs,Dr. Jeffs has served as a member of the Board since February 2018. He recently served as President and co-Chief Executive Officer of United Therapeutics Corporation from January 2015 to June 2016. Dr. Jeffs joined United Therapeutics in 1998 as director of research, development, and medical and served as its President and Chief Operating Officer from April 2001 to December 2014. He also served as a member of its board of directors from 2001 to 2016. Before joining United Therapeutics, he held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co. Dr. Jeffs is the co-founder and co-owner of Bull City Select Investments, an investment firm focused on in-licensing and development of early-stage biopharma assets. Dr. Jeffs is a member of the boards of directors of the following public companies: Albireo Pharma, Inc., Axsome Therapeutics, Inc., Dova Pharmaceuticals, Inc. and Sangamo Therapeutics, Inc. Dr. Jeffs received his B.A. in Chemistry from Duke University and his Ph.D. in Pharmacology from the University of North Carolina School of Medicine. - Roger Jeffs，他获得杜克大学（Duke University）的化学学士学位，并获得the University of North Carolina的药理学博士学位。他于1998年加入United Therapeutics公司，并担任研究、开发和医疗董事。他于2000年被任命为研究、开发和医疗的副总裁，并于2001年担任现任职务，即总裁兼首席营运官。从1993年到1995年，他曾任职Burroughs Wellcome & Company，在那里他曾担任Flolan（美国fda批准的首个治疗肺动脉高血压患者药物）的临床研究小组的一员。从1995年到1998年，他曾任职Amgen公司，在那里他曾担任全球临床传染病项目的领导人。他目前领导我们的全球临床、商业、制造业、监管、药物警戒和业务开发工作。自2002年以来，他担任United Therapeutics公司的董事。
- Roger Jeffs,Dr. Jeffs has served as a member of the Board since February 2018. He recently served as President and co-Chief Executive Officer of United Therapeutics Corporation from January 2015 to June 2016. Dr. Jeffs joined United Therapeutics in 1998 as director of research, development, and medical and served as its President and Chief Operating Officer from April 2001 to December 2014. He also served as a member of its board of directors from 2001 to 2016. Before joining United Therapeutics, he held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co. Dr. Jeffs is the co-founder and co-owner of Bull City Select Investments, an investment firm focused on in-licensing and development of early-stage biopharma assets. Dr. Jeffs is a member of the boards of directors of the following public companies: Albireo Pharma, Inc., Axsome Therapeutics, Inc., Dova Pharmaceuticals, Inc. and Sangamo Therapeutics, Inc. Dr. Jeffs received his B.A. in Chemistry from Duke University and his Ph.D. in Pharmacology from the University of North Carolina School of Medicine.
高管简历
中英对照 | 中文 | 英文- Herriot Tabuteau
Herriot Tabuteau，本公司的创始人，自2012年1月本公司成立之时起，担任首席执行官、董事长。他还是Antecip Capital LLC（原Versant Capital Management LLC）的创始人，这是本公司的大股东之一；2003年起，担任其管理合伙人。他还是Antecip Bioventures II LLC的管理合伙人。创办本公司之前，他是 Healthco/S.A.C. Capital （现HealthCor） 的高级分析师、合伙人，负责生物技术、基因组、仪表行业投资组合。此前，他是Kingdon Capital的医疗保健行业分析师。职业生涯之初，他是Goldman Sachs的投资银行分析师，后来成为Banc of America Securities的高级研究分析师，负责医院供应品行业。他在Yale University School of Medicine获得医学博士学位，在Wesleyan University获得分子生物与生物化学学士学位。
Herriot Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. He is also the founder of Antecip Capital LLC formerly Versant Capital Management LLC, one of our principal stockholders, for which Dr. Tabuteau has been the managing member since 2003. Dr. Tabuteau is also the managing member of Antecip Bioventures II LLC. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.- Herriot Tabuteau，本公司的创始人，自2012年1月本公司成立之时起，担任首席执行官、董事长。他还是Antecip Capital LLC（原Versant Capital Management LLC）的创始人，这是本公司的大股东之一；2003年起，担任其管理合伙人。他还是Antecip Bioventures II LLC的管理合伙人。创办本公司之前，他是 Healthco/S.A.C. Capital （现HealthCor） 的高级分析师、合伙人，负责生物技术、基因组、仪表行业投资组合。此前，他是Kingdon Capital的医疗保健行业分析师。职业生涯之初，他是Goldman Sachs的投资银行分析师，后来成为Banc of America Securities的高级研究分析师，负责医院供应品行业。他在Yale University School of Medicine获得医学博士学位，在Wesleyan University获得分子生物与生物化学学士学位。
- Herriot Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. He is also the founder of Antecip Capital LLC formerly Versant Capital Management LLC, one of our principal stockholders, for which Dr. Tabuteau has been the managing member since 2003. Dr. Tabuteau is also the managing member of Antecip Bioventures II LLC. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.
- Constance Ames
Constance Ames，2015年2月起，担任本公司的财务副总裁。加入本公司之前，她任职于Keryx Biopharmaceuticals, Inc.；于2010年加入该公司，最后的职务是财务与会计高级总监，在该公司从发展阶段的企业转变成为完全整合的商业组织的过程中，她在扩张财务和会计部门发挥了重要的作用。她还曾负责领导该公司涉及Securities and Exchange Commission的相关规章的合规工作。加入Keryx之前，她任职于独立的注册会计师公司Deloitte and Touche, LLP，曾是一名高级助理。她在 Ithaca College获得会计学士学位，是American Institute of Certified Public Accountants的会员。
Constance Ames has served as Keryx Biopharmaceuticals, Inc. Vice President, Finance since February 2015. During her tenure there, Ms. Ames played a critical role in growing the finance and accounting department through Keryx's transition from a development-stage company to a fully integrated commercial organization. She was also responsible for leading Keryx's compliance with Securities and Exchange Commission rules and regulations. Prior to joining Keryx, she was with Deloitte and Touche, LLP, independent certified public accountants, where she served as a senior associate. Ms. Ames received a Bachelor of Science in accounting from Ithaca College and is a member of the American Institute of Certified Public Accountants.- Constance Ames，2015年2月起，担任本公司的财务副总裁。加入本公司之前，她任职于Keryx Biopharmaceuticals, Inc.；于2010年加入该公司，最后的职务是财务与会计高级总监，在该公司从发展阶段的企业转变成为完全整合的商业组织的过程中，她在扩张财务和会计部门发挥了重要的作用。她还曾负责领导该公司涉及Securities and Exchange Commission的相关规章的合规工作。加入Keryx之前，她任职于独立的注册会计师公司Deloitte and Touche, LLP，曾是一名高级助理。她在 Ithaca College获得会计学士学位，是American Institute of Certified Public Accountants的会员。
- Constance Ames has served as Keryx Biopharmaceuticals, Inc. Vice President, Finance since February 2015. During her tenure there, Ms. Ames played a critical role in growing the finance and accounting department through Keryx's transition from a development-stage company to a fully integrated commercial organization. She was also responsible for leading Keryx's compliance with Securities and Exchange Commission rules and regulations. Prior to joining Keryx, she was with Deloitte and Touche, LLP, independent certified public accountants, where she served as a senior associate. Ms. Ames received a Bachelor of Science in accounting from Ithaca College and is a member of the American Institute of Certified Public Accountants.